Clearpoint Neuro Inc. · NASDAQ:CLPT

Clearpoint Neuro — J.P. Morgan Healthcare Conference 2024

18 slides from Clearpoint Neuro's conference presentation, Jan 8, 2024

  1. Slide 1: When your path is unclear, we point the way

    CLEARPOINT NEURO WHEN YOUR PATH IS t WE POINT THE WAY. Nasdaq: CLPT January 2024

  2. Slide 2: Forward-looking statements

    © 2 0 2 4 C L E A R P O I N T N E U R O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and

  3. Slide 3: Our Company

    © 2 0 2 4 C L E A R P O I N T N E U R O 3 Our Company

  4. Slide 4: • • • • • • • • • • • *Including owned and

    • • • • • • • • • • • *Including owned and licensed patents 4

  5. Slide 5: The ClearPoint Neuro Navigation System

    The ClearPoint® Neuro Navigation System Leverage live MR Imaging to Decide, Guide, and Confirm with sub-millimetric accuracy Pre-Plan Trajectory and Automatically Guide Precision Confirm Quality of Delivery Decide Entry Point Adjustments Prior to Insertion Into Permanent Record 3, CLEARPOINT © 2024

  6. Slide 6: System components

    ClearPoint Neuro Navigation Software v.2.1 ClearPoint Array Software v.1.2 ClearPoint Maestro® Brain Model Inflexion® Head Fixation Frame MRI Coils MRI Monitor Multi-Positional Head Fixation Frame Accessory Kit (4Fr, 5Fr, and 7Fr Available) SmartFrame Array® Kit Components Capital Hardware and Softw

  7. Slide 7: Revenue history and 2024 guidance

    7 (A) (B) (D,E) © 2 0 2 4 C L E A R P O I N T N E U R O (A) Estimated and subject to revision (B) Unaudited as of, and for the quarter ended December 31, 2023 (C) Including owned and licensed patents (D) For the Trailing Twelve Months (TTM) (E) Unaudited as of, and for the quarter ended September 30

  8. Slide 8: Facilities and quality systems

    © 2 0 2 1 C L E A R P O I N T N E U R O 8 • 1,500 sq. ft Class 8 Clean Room with Expansion Capability • 1,300 sq. ft Dedicated R&D Lab Space • ISO 13485/MDSAP/EU MDR Certified Quality System • Successful Audit Outcomes from Global Regulatory Bodies and Pharma • Training Facility with over 100 Surgeo

  9. Slide 9: A Therapy Enabling Platform

    A Therapy Enabling Piatforms 75+ Centers i in the US if uc san Frahclsod eae “University 0 : é 2 > “Stanford University University of niger j arleeR awan iecki Szpital Brodnowski (Warsaw, Poland) “Tile Packard Children’s Hospital ©. University of Minnesota «Children’s N "Hopital Fondation Rothschild

  10. Slide 10: Compatible with all major MRI scanners

    © 2 0 2 4 C L E A R P O I N T N E U R O 10 VISUALASE ClearPoint Navigation is Compatible with all Major Diagnostic and Intraoperative MRI Scanners …with 50+ industry and academic partners *In approved clinical trials and preclinical studies.

  11. Slide 11: Addressable indications and market opportunity

    Parkinson’s Disease 1,000,0001 60,0001 • $270 M - $1.35 B Drug Resistant Epilepsy 1,000,0002 11,0003 • $49.5 M - $198 M Refractory Essential Tremor 3,500,0004 60,0005 $180 M - $1.08 B Brain Tumors (n=3)6 35,0007,8 13,3007,8 $33.3 M - $300 M Severe Obsessive-Compulsive Disorder 500,0009,10 10,0009,10

  12. Slide 12: Citations and footnotes

    © 2 0 2 4 C L E A R P O I N T N E U R O 12 1. “Parkinson’s Disease Statistics,” Parkinson’s News Today, https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older 2. Neurona Therapeutics. (2021 November 4). Neurona Therapeutic

  13. Slide 13: 4 Pillar Growth Strategy by 2025

    NEW THERAPY DEVICES NEURO NAVIGATION FOR DBS BIOLOGICS & DRUG DELIVERY 20252024 4 Pillar Growth Strategy by 2025 Development Pipeline Over the Next Two Years Full Market Release for PRISM Neuro Laser Integrate Tumor Segmentation Software Activate Maestro Ablation Coverage & A.I. Predictive Modeling

  14. Slide 14: Development pipeline

    © 2 0 2 4 C L E A R P O I N T N E U R O 14 Radially Branching Cell therapy Devices ClearPoint Orchestra™ Head Fixation Frame Spinal Infusion Anchoring Devices PRISM 3.0 T & 1.5 T Compatible Systems (1.5 T Compatibility not yet FDA Cleared) Array 1.2 Parallel Trajectory Tumor Feature *Biologics & Dru

  15. Slide 15: ClearPoint Maestro Brain Model

    © 2 0 2 4 C L E A R P O I N T N E U R O 15 • FDA Cleared, Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects • Auto-Segmentation for Device Targeting • Direct Navigation in Clinical Trials for Drug Delivery • Longitudinal Comparison for Pharma Trial

  16. Slide 16: Investment highlights

    © 2 0 2 4 C L E A R P O I N T N E U R O 16 Unique platform technology with 10+ years of commercial experience enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders Large, growing number of customer and partner sites of 75+ leading Neurosurgery

  17. Slide 17: Slide 17

  18. Slide 18: ClearPoint Neuro

    CLEARPOINT NEURO

ClearPoint Neuro — J.P. Morgan Healthcare Conference 2024 on 6ix